These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2832091)

  • 1. Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate.
    Creaven PJ; Zakrzewski SF; Greco WR; Madajewicz S; Mittelman A; Pontes JE; Karakousis C; Takita H; Proefrock A
    Cancer Chemother Pharmacol; 1988; 21(2):122-8. PubMed ID: 2832091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
    Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
    Rafi I; Boddy AV; Calvete JA; Taylor GA; Newell DR; Bailey NP; Lind MJ; Green M; Hines J; Johnstone A; Clendeninn N; Calvert AH
    J Clin Oncol; 1998 Mar; 16(3):1131-41. PubMed ID: 9508200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
    Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
    Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
    Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
    J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
    Rinaldi DA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogs.
    Zakrzewski SF; Pavelic Z; Greco WR; Bullard G; Creaven PJ; Mihich E
    Cancer Res; 1982 Jun; 42(6):2177-83. PubMed ID: 7074598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies with a new antifolate 2,4-diamino-5-adamantyl-6-methylpyrimidine (DAMP): tissue distribution and disposition of 2,4-diamino-5-adamantyl-6-methylpyrimidine and its metabolite.
    Zakrzewski SF; Dave C; Mead LH; Deluomo DS
    J Pharmacol Exp Ther; 1978 Apr; 205(1):19-26. PubMed ID: 633083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
    Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
    Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
    Thödtmann R; Depenbrock H; Dumez H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
    J Clin Oncol; 1999 Oct; 17(10):3009-16. PubMed ID: 10506594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
    Budman DR; Johnson R; Barile B; Bowsher RR; Vinciguerra V; Allen SL; Kolitz J; Ernest CS; Kreis W; Zervos P; Walling J
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):525-31. PubMed ID: 11459206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
    O'Dwyer PJ; Laub PB; DeMaria D; Qian M; Reilly D; Giantonio B; Johnston AL; Wu EY; Bauman L; Clendeninn NJ; Gallo JM
    Clin Cancer Res; 1996 Oct; 2(10):1685-92. PubMed ID: 9816117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
    Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
    Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
    Burris H; Irvin R; Kuhn J; Kalter S; Smith L; Shaffer D; Fields S; Weiss G; Eckardt J; Rodriguez G
    J Clin Oncol; 1993 May; 11(5):950-8. PubMed ID: 8098059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
    Ratliff AF; Wilson J; Hum M; Marling-Cason M; Rose K; Winick N; Kamen BA
    J Clin Oncol; 1998 Apr; 16(4):1458-64. PubMed ID: 9552052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.